Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

WILMINGTON, Del.--(BUSINESS WIRE)--Dec 7, 2025-

Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug

The FDA granted Breakthrough Therapy status to Incyte's experimental treatment for a rare blood cancer. Incyte stock is basing near five-year highs. The post Incyte Gets FDA Breakthrough Therapy Fast Track For Rare Blood Cancer Drug appeared first on Investor's Business Daily.